EBR Achieves Tenth US Commercial Implant Milestone

EBR Systems, Inc. (ASX: EBR) has announced the successful completion of its tenth commercial implant of the WiSE® System in the United States, marking an important step in its pilot launch phase. The company confirmed that additional implants have followed this milestone, highlighting growing physician and patient adoption even before reimbursement programs take effect. Several procedures were performed by Dr. Rahul Doshi at HonorHealth in Arizona, with results reinforcing the clinical value of physiologic leadless pacing compared to conventional cardiac resynchronization therapy (CRT).

EBR’s pilot strategy prioritises higher utilisation across select sites, a model that will continue under the upcoming limited market release (LMR) scheduled for October 2025. This timeline coincides with the start of the New Technology Add-On Payment (NTAP) for inpatients and preliminary approval for Transitional Pass-Through (TPT) reimbursement in outpatients. CEO John McCutcheon noted that early adoption demonstrates strong clinical interest and positions EBR well for broader commercialisation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com